Chief Medical Officer
ArteraAI
Chief Medical Officer
ArteraAI
Delivers CLIA-certified multi-modal prostate cancer test
Salary Range: 360000 to 410000 (Currency: USD) (Pay period: per-year-salary)
The Chief Medical Officer (CMO) is a core member of the executive leadership team and the primary medical spokesperson for the company. This company leader is responsible for setting and communicating the medical vision for where the company should go by identifying the most important unmet clinical needs and ensuring that these align with business impact. The CMO will shape the company’s clinical strategy, build a strong pipeline of high-quality data and strategic collaborators, communicate with key opinion leaders, and guide the organization toward innovations that will make a measurable difference for cancer patients. The CMO must be a highly credible and influential voice within the cancer community, with trusted relationships among leading oncologists and KOLs that can accelerate adoption and shape standards of care.
This role requires a practicing or former oncologist (radiation oncologist or medical oncologist) who deeply understands what will be clinically impactful and can translate that insight into company direction. The defining quality of a strong CMO is their ability to craft a medical strategy and lead strong teams to execute the strategy.
Define and communicate a clear medical vision that aligns clinical opportunities with the company’s mission and commercial strategy.
Identify and prioritize clinical unmet needs with the greatest potential for patient benefit and market impact.
Serve as the primary medical spokesperson for the company with internal teams, investors, collaborators, and the broader oncology community.
Anticipate shifts in oncology practice, ensuring the company is positioned ahead of the curve.
Oversee strategies to build and maintain a high-quality, scalable clinical data pipeline that fuels product development, validation, and innovation.
Cultivate a strong network of academic partners, clinical collaborators, and key opinion leaders to advance the company’s scientific and commercial goals.
Ensure clinical evidence generation plans support both scientific credibility and payer adoption.
Partner closely with product, R&D, and commercial teams to integrate clinical insight into portfolio strategy.
Translate complex clinical and scientific data into actionable business decisions.
Lead teams to design, execute, and interpret clinical studies that support product development and to educate the clinical impact of the test with clinicians.
Lead team of physician leaders synthesizing collective clinical voice and expertise
Deep understanding of oncology practice, unmet needs, and pathways to adoption
Comes with a strong network of KOLs and research communities.
Experienced in developing and guiding programs spanning multiple tumor types
Visionary thinker who anticipates shifts in the clinical landscape and ensures research addresses the most impactful questions.
Skilled and persuasive communicator who inspires confidence across clinical, scientific, and business stakeholders.
Proven ability to build high-value partnerships and collaborative relationships to fuel a robust data pipeline as well as maintain strong relationships with influential groups, like guidelines committees.
Decisive leader who can cut through uncertainty, guide teams with clarity, and balance scientific rigor with business priorities.
Ensures the medical organization remains quick, nimble, and adaptable in a rapidly evolving oncology landscape
2 years of industry leadership experience
3 years of people and/or laboratory management experience
Willing to travel up to 30% per month for conferences, leadership team meetings, clinician engagements
ArteraAI develops personalized prostate cancer therapy solutions using multi-modal deep learning. Its flagship offering, the ArteraAI Prostate Test, is a high-complexity CLIA-certified clinical laboratory test performed in-house and used in clinical care. The test analyzes diverse data through advanced AI to tailor treatment decisions for individual patients. Unlike many competitors, ArteraAI integrates randomized phase III trial-informed science, in-house product development, and routine publications to support credibility, and targets a shift toward personalized, data-driven prostate cancer therapies. The company's goal is to equip healthcare providers with reliable, data-backed tools to personalize treatment plans, improving outcomes for patients while expanding adoption across hospitals, clinics, and other care settings.
Explore more opportunities at ArteraAI